HOME >> BIOLOGY >> NEWS
Experimental hantavirus vaccine elicits strong antibody response in primates

For the first time, scientists have demonstrated that an experimental vaccine to hantavirus pulmonary syndrome (HPS), a highly lethal disease, elicits a strong neutralizing antibody response in laboratory animals--a response that is key to preventing the virus from causing infection.

In addition, the antibodies, produced in nonhuman primates that received the vaccine, protected hamsters from disease even when administered 5 days after exposure.

These findings provide proof of concept in nonhuman primates for a vaccine against HPS, as well as for post exposure prophylactic treatment of HPS and a related disease known as hemorrhagic fever with renal syndrome (HFRS).

In an article published in last month's Journal of Virology, investigators at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) describe using a naked DNA approach to develop a hantavirus vaccine. The technique involves vaccination with plasmid DNA that encodes a specific hantavirus gene. When the plasmid DNA is introduced into the cells of a vaccine recipient, using a harmless device called a "gene gun," the cloned gene is expressed and presented to the immune system.

According to senior author Jay W. Hooper, Ph.D., the USAMRIID team constructed an expression plasmid containing the full-length M genome segment of Andes virus, a South American hantavirus. Vaccination with the plasmid elicited a potent neutralizing antibody response in rhesus macaques that were vaccinated a total of four times at three-week intervals.

To look at the duration of that response, the team collected serum samples for about six months. The monkeys who received the Andes vaccine displayed robust antibody levels as long as 25 weeks after the last vaccination.

Hantaviruses are carried by rodents and have caused epidemics in Europe, Asia, and the Americas. Some cause HPS, while others are responsible for the more common HFRS. The viruses are patho
'"/>

Contact: Caree Vander Linden
Caree.Vander-Linden@amedd.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
23-Oct-2003


Page: 1 2 3

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/8/2019)... ... May 08, 2019 , ... RG+A, Inc., a leading healthcare ... has agreed to serve as Chief Executive Officer and pharmaceutical leader Dr. Martin ... They will join Chairman and Founder Roger Green to create a three-person executive ...
(Date:5/8/2019)... ... 08, 2019 , ... FISO Technologies proudly presents the innovative ... lead-in fiber of 100 microns. With dimensions smaller than any competitive product, FISO ... world leader in the development of fiber optic sensors & signal conditioners used ...
(Date:5/2/2019)... ... , ... Philadelphia intellectual property law firm Panitch Schwarze ... a registered patent agent, has joined the firm as a new member of ... support and scientific expertise in the pharmaceutical and biotechnical arts and assists in ...
Breaking Biology News(10 mins):
(Date:4/15/2019)... ... April 15, 2019 , ... Sirrus, Inc., a ... million bench plant expansion to increase production of methylene malonate monomers and oligomers. ... construction of Sirrus’ full-scale production facility, which is scheduled to break ground in ...
(Date:4/9/2019)... ... April 09, 2019 , ... USDM Life Sciences ... life sciences organizations to accelerate innovation and maximize productivity, announces that nearly 100 ... 12 months. , USDM’s Cloud Assurance is a managed subscription service ...
(Date:4/8/2019)... SAN FRANCISCO (PRWEB) , ... April 08, 2019 , ... ... to accredited investors a $15 million preferred equity investment in the privately held pharmaceutical ... dysfunction. Its leading drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific Diagnostics announced today ... with a second stage of funding for Specific’s Reveal™ rapid antibiotic susceptibility test ... of the $1.7 million already awarded by CARB-X. The additional $1.7M will enable ...
Breaking Biology Technology:
Cached News: